Cytokinetics Inc (CYTK)

Debt-to-equity ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Long-term debt	US$ in thousands	58,384	60,885	62,492	64,110	63,810	63,544	62,344	61,165	47,367	30,203	35,538	40,874	46,209	45,920	45,631	45,340	45,052	44,762	44,473	36,382
Total stockholders’ equity	US$ in thousands	-386,323	-438,801	-333,115	-229,020	-107,900	-15,977	111,414	116,261	243,863	249,020	16,489	67,846	113,383	149,605	-78,080	-45,711	-10,937	-19,869	-4,896	3,372
Debt-to-equity ratio		—	—	—	—	—	—	0.56	0.53	0.19	0.12	2.16	0.60	0.41	0.31	—	—	—	—	—	10.79

December 31, 2023 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $58,384K ÷ $-386,323K
= —

The debt-to-equity ratio for Cytokinetics Inc has not been provided for the quarters of Q4 2023, Q3 2023, Q2 2023, and Q1 2023. However, based on the available data, the trend in the debt-to-equity ratio for the company over the last two quarters of 2022 shows an increase, from 1.68 in Q1 2022 to 1.77 in Q2 2022. This indicates a higher level of debt relative to equity in the company's capital structure during this period.

It would be important to monitor the debt-to-equity ratio for Cytokinetics Inc in future quarters to assess if this trend continues or if there are any significant changes that may impact the company's financial health and risk profile. A rising debt-to-equity ratio can suggest increasing financial leverage and potential risks associated with debt repayment obligations.